GenrAb

GenrAb, Inc. develops first-in-class neuroprotective therapies using a unique approach of identifying naturally occurring, human neuroprotective antibodies from the cerebrospinal fluid of patients with neurological diseases. Their lead candidate, TGM-010, is a fully-human antibody designed to cross the blood-brain barrier and reduce neurological disability. GenrAb aims to create high-impact medicines to address the significant unmet needs in neurodegenerative disease treatment.

+ 0 Upvotes
Buy Funded Startups lists